[Newsmp]“In pursuit of a world without lung cancer deaths.“AstraZeneca showcased its lung cancer leadership at the World Conference on Lung Cancer (WCLC 2023).At the conference, the highlight session was the Plenary-Presidential Symposium, which featured over 40 abstracts, including FLAURA2, which d

[Newsmp] South Korea's Drug Reimbursement Evaluation Committee under the Health Insurance Review and Assessment Service (HIRA) has approved three drugs, including Koselugo for neurofibromatosis.During the 10th committee meeting on the 7th, HIRA has passed insurance coverage of four drugs, including

[Newsmp] After a significant drop in July, the number of Ministry of Food and Drug Safety medications has returned to its previous levels.According to the MFDS information platform (https://nedrug.mfds.go.kr/), pharmaceutical approvals for August totaled 132, surpassing the first-half monthly averag

[Newsmp] Starting from September, the South Korean pharmaceutical benefit list will include the diabetes combination drug Envlomet SR Tab. (Daewoong Pharmaceutical), the pompe disease therapy Nexviazyme (Sanofi), the heart failure treatment Verquvo (Bayer), and the growth hormone drug Ngenla (Pfizer

[Newsmp] Big pharma's oncology businesses showed a clear difference in performance.The quarterly reports focused on cancer from big pharma, compiled by Newsmp, indicate that the leading group such as companies, including MSD, Johnson & Johnson (Janssen), AstraZeneca, and Novartis, all recorded high

[Newsmp] Global pharmaceutical companies are struggling under the influence of the endemic.The second quarter saw some improvement over the first quarter, but most companies' growth rates remained below 7%.In the midst of this, Novo Nordisk and Eli Lilly, whose sales of dual GIP/GLP-1 receptor agoni

[Newsmp] GLP-1 analogs are expanding their sales beyond diabetes to obesity, leading to significant growth in size.According to each company's report, major injection-type metabolic disease treatments such as insulin, GLP-1 analogs, and dual GIP/GLP-1 receptor agonists are increasingly becoming majo

[Newsmp] As next-generation cancer drugs like CAR-T, antibody-drug conjugates (ADCs), and cancer immunotherapy are witnessing promising outcomes, treatments for SMA, criticized for their hefty price tags, find themselves at a standstill.According to the quarterly reports of global big pharma, the ma

[Newsmp] In the midst of a recovery to its previous state after a substantial decline in the first quarter in the autoimmune disease treatment market, Humira, Dupixent, and Stelara are in command.According to the reports of major global Big Pharma, the sales of large items in the autoimmune disease

[Newsmp] The Ministry of Food and Drug Safety on the 3rd announced the approval of the new psoriasis drug Sotyktu (ingredient: deucravacitinib) imported by BMS Korea.Sotyktu is an oral psoriasis drug that selectively targets and inhibits TYK2, a protein that plays a key role in the immune system."We

[Newsmp] We are rare, but we are special.Sanofi-Aventis, the global leader in the rare disease treatment market, has received approvals for new therapies in three rare disease fields in 2023 alone.Among the three new drugs approved in July, Enjaymo (ingredient: sutimlimab) and Xenpozyme (ingredient:

[Newsmp] The Ministry of Food and Drug Safety approved the orphan drug Tecvayli (ingredient: teclistamab) for the treatment of multiple myeloma on July 26.Multiple myeloma is a type of blood cancer that occurs when plasma cells, a type of white blood cell that helps the immune system, abnormally div

[Newsmp] The health insurance coverage list now includes Onureg, the medication for treating acute myeloid leukemia by BMS Korea.Pfizer Korea’s breast cancer treatment Ibrance has been listed as a tablet followed by capsules, and Sanofi’s type 2 inflammatory disease treatment Dupixent has been liste

[Newsmp] Korea’s Ministry of Food and Drug Safety said on Wednesday it has approved Sanofi-Aventis Korea’s acid sphingomyelinase deficiency (ASMD) therapy Xenpozyme (ingredient: olipudase alfa).ASMD arises from a deficiency in an essential enzyme responsible for breaking down a complex lipid known a

[Newsmp] In the first half, the Ministry of Food and Drug Safety approved a slightly lower number of clinical trials compared to the corresponding period in the previous year.According to the MFDS information platform (https://nedrug.mfds.go.kr/), 225 companies obtained approvals for 556 clinical tr

[Newsmp] On the 12th, the Ministry of Food and Drug Safety granted approval to Sanofi's Enjaymo (ingredient: sutimlimab) for treating hemolysis in adult patients with cold agglutinin disease.Enjaymo is indicated for hemolytic therapy in adult patients with autoimmune hemolytic anemia (AIHA), a type

[Newsmp] Daiichi Sankyo Korea surpassed KRW 250 billion in annual sales last year, securing the top position in revenue among Japanese pharmaceutical companies operating in Korea.The audit reports showed that Daiichi Sankyo achieved sales of KRW 253.2 billion last year, recording a growth of 3.2% co

[Newsmp] The number of new entries in the patent list of the Ministry of Food and Drug Safety significantly decreased, not exceeding 100 cases during the last six months.According to the MFDS information platform (https://nedrug.mfds.go.kr/), the Ministry of Food and Drug Safety's patent list for th

[Newsmp] Individual investors' net buying amount for Samsung Biologics, among the 47 pharmaceutical index components during the first half of the year, amounted to KRW 336.5 billion, the Korea Exchange said.Daewoong Pharmaceutical exceeded KRW 101.8 billion, surpassing KRW 100 billion, while Green C

[Newsmp] As pharmaceutical and bio companies continue to underperform, the market capitalization of the pharmaceutical index is experiencing a significant decline, jeopardizing the KRW 100 trillion mark.According to the Korea Exchange, the combined market capitalization of the 47 constituent stocks